Bharat Biotech Submits Trial Data for Children in 2-18 Ys Age Group, May Choose Nasal Vaccines for Booster
Bharat Biotech has completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age in September. The company has now submitted the trial data for DCGI’s approval.